SkyePharma

Activities: Manufacturing Drug Delivery Pharmaceutical

Trending Articles

  1. Scleroderma treatment by Certa Therapeutics granted US FDA fast track FT011 is a novel, first-in-class oral therapy for the treatment of chronic fibrosis in multiple organs
  2. Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222 Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
  3. Indian government bans three medicines owing to health risks Decision follows strong stand on suspending marketing of all drugs prohibited for sale in other countries, including the US, UK, EU and Australia
  4. Dickson achieves ISO 14001 certification ISO 14001 certification highlights a companies' long-term efforts to manage its environmental impact
  5. The key role of IVDs in healthcare: challenges to commercialisation and access In simple terms, in vitro diagnostic (IVD) tests are done on samples such as blood or tissue that have been taken from the human body. IVDs can detect diseases, conditions and...

Upcoming event

Making Pharmaceuticals

23–24 April 2024 | Exhibition | Coventry, UK See all

Related Content

Drug Delivery

SkyePharma signs exclusive licensing agreement to access Lucideon’s abuse deterrent drug delivery technology

First product to be developed for the growing $11bn US opioid market
Manufacturing

Skyepharma installs MG2 Planeta

To address its needs for the production of pilot and clinical batches of inhalation products and third party projects
Research & Development

David Lescuyer joins SkyePharma as Executive Vice President, Oral Business

He will be responsible for Skyepharma’s Oral Business including, after 30 June, the manufacturing operations in Saint-Quentin Fallavier, France
Finance

Vectura and Skyepharma agree to merge

Respiratory drug delivery specialists will become an industry-leading airways-related speciality business
Research & Development

Skyepharma acquires novel inhaled therapy platform

New product opportunity to be developed as an anti-inflammatory treatment for COPD
Drug Delivery

Flutiform sales drive growth at SkyePharma

Plans to raise £112m in capital to pay off bond debt and strengthen product pipeline
Drug Delivery

SkyePharma reports strong revenue growth

Underpinned by sales of Flutiform and use of proprietary dry powder formulation technology in GSK product
Subscribe now